Caldolor Launch Boosts Cumberland Pharmaceuticals Earnings

Nashville’s Cumberland Pharmaceuticals beat earnings targets in the third quarter of this year. During the three month period, the drug maker launched its injectable ibuprofen and completed an initial public offering of stock.

Earnings were up only slightly for the quarter due to significant investment in the launch of Caldolor. Cumberland Pharmaceuticals nearly doubled last year’s expenses to push the patented drug to hospitals around the country. The company has a sales force of more than 100 working on the injectable drug.

Cumberland has filed more patent applications to protect the method of dosing intravenously. Caldolor is the first drug approved by the FDA to treat fever through an IV. The drug is also used in patients who are allergic to other pain medications.

Aside from new drug revenues, Cumberland raised $85 million in August with an IPO. That’s led to a huge increase in cash on hand. CEO A.J. Kazimi says the company intends to use that capital to further support the Caldolor launch and add new drugs to the company’s product line.

Please keep your community civil. Comments will be moderated prior to posting, and Nashville Public Radio reserves the right to approve them at its discretion. Comments containing links promoting goods, services - even noble organizations - will not be published. Your comments may include external links, but all comments with links will be delayed as they are reviewed. Comments containing profanity will be rejected.